Merck (NYSE: MRK) has taken its shareholders on a wild ride of late -- from last March's record high of more than $130 to this May's low near $76 back to its current price of just a little more than ...

Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.

Turning $10,000 into $50,000 in about five years would require a compound annual growth rate (CAGR) of almost 38%. That's an extremely tough task for any corporation, but can Merck (NYSE: MRK), a ...

View Merck & Co., Inc. MRK stock quote prices, financial information, real-time forecasts, and company news from CNN.

Get the live share price of Merck & Company Inc (MRK), including intraday charts, historical performance, key financials, and ...

Forbes contributors publish independent expert analyses and insights. As a brief background, Merck develops pharmaceutical products for human health across various therapeutic areas and also creates ...

The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

Merck MRK announced that the phase II CADENCE study, which evaluated its newly launched pulmonary arterial hypertension (“PAH”) drug Winrevair, for treating adults with combined post and precapillary ...

Merck (MRK) closed the most recent trading day at $106.45, moving +1.13% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.19%. At the same time, the ...

Merck's biggest growth drivers are cancer drug Keytruda and its HPV vaccine franchise, Gardasil and Gardasil 9. However, both are facing issues. Keytruda will experience a patent cliff by 2028, ...